Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo biological standardization of Dermatophagoides allergen extracts
2024-514108-15-00Phase 2Withdrawn
- Sponsor
- Advanced Outcomes Research
- Start
- Sep 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dermatophagoides pteronyssinus in allergic rhinitis (AR), allergic asthma and house dust mite allergy (2 arms), sponsored by Advanced Outcomes Research. Primary endpoints: Wheal area after prick test, Dose-response relationship and 1 more. Planned start Sep 2024; status: withdrawn.
02
Drugs
dermatophagoides pteronyssinus
03
Conditions
allergic rhinitis (AR)allergic asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2024-514108-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514108-15-00.